Response to Spangenberg and Koo, "Response to Schwarz C.W., et al. 'Comparative 2-year drug survival of bimekizumab and brodalumab in second-line treatment of psoriasis".
Schwarz CW, Loft N, Skov L
Journal of the American Academy of DermatologyIn the feed 5 Oct 2026, published online 5 Oct 2026, issue 2026 Oct 05, added to PubMed 5 Oct 2026
Topics: Psoriasis
Abstract
PubMed has no abstract for this paper, as is usual for research letters, correspondence and editorials. The publisher’s page has the full paper.
PMID 42833492 · DOI 10.1016/j.jaad.2026.09.116